AbbVie: FDA approval in ulcerative colitis
"With more than one million people living with ulcerative colitis, the U.S. has one of the largest populations affected by this disease, and the numbers continue to grow," the healthcare group highlights.
This approval is supported by two Phase III clinical trials, which showed that clinical remission, the primary endpoint, was achieved at the same time as endoscopic improvement, the key secondary endpoint.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction